Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. - Wikidata - awgldk - TriplyDB

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

http://www.wikidata.org/entity/Q36364013

about

Therapeutic Drug Monitoring of Posaconazole: an Update Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections Invasive mold infections in solid organ transplant recipients Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective Fundament and Prerequisites for the Application of an Antifungal TDM Service Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies Efficacy of PTX3 and posaconazole combination in a rat model of invasive pulmonary aspergillosis Last generation triazoles for imported eumycetoma in eleven consecutive adults Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.A Single Center Experience for Antifungal Prophylaxis in Patients with Acute Myelogenous Leukemia.Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.A combination approach to treating fungal infections.Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events.Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis.Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations.Pharmacologic and clinical evaluation of posaconazole.Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Safety of posaconazole.Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.Our 2014 approach to breakthrough invasive fungal infections.Posaconazole salvage treatment for invasive fungal infection.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole.Our 2015 approach to invasive pulmonary aspergillosis.Acid suppressing therapy as a risk factor for Candida esophagitis.Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.New facets of antifungal therapy.Antifungal agents and liver toxicity: a complex interaction.

P2860

Q26746016-2071F735-3920-49CE-BA1E-5A938833A2EB Q26771180-7505C46C-4F4A-46E5-9A50-758193CBF822 Q26823811-E5E27D54-A38D-4561-946D-B414838E8284 Q27009221-6CAEAD1F-F74C-41EC-9BDC-157E75054B1D Q28085352-6CF48DAE-633E-44A1-B1B7-F3DA74DAF5B7 Q33798313-11903095-8D1D-43EC-9B6E-C32A5D9C9E16 Q33880412-4014A02A-7CDB-4AD1-84E3-12E3D1B1D9DC Q34298803-43385D7E-DBC6-49E3-ABC2-1C912FDD5A90 Q34315079-C5A32D3C-0E68-4858-BC3E-A0ACD9CA4BCB Q34532546-274C6854-B90C-4E60-85C6-96DCD8E60A03 Q34596313-C1DECE9C-8D45-490C-BE58-6F636EB99AFC Q34596750-29FFCDF5-1DD2-49AD-B26C-05B624747702 Q34596950-5EBC9A67-D942-4537-89E0-EE5763C23311 Q35262607-FA16F230-F2D4-4AAA-9422-B92A16CA56E1 Q35736934-E0B707D9-136C-4A25-9C2B-412877E4CD7F Q35860057-94D2950A-0C01-450E-85EE-7F3FAC7CA6E0 Q36305684-290E3BFE-6D1B-4D77-AAF2-D80011803AD7 Q36406975-34B1078B-30A7-42EA-8D92-1A9782F6E826 Q36849416-53D87103-CB8D-4DF4-A283-CF22177AA98F Q36933524-75FCED5C-9C9C-4AE3-9675-58E2D5DFB3CD Q37203849-A3ED8407-E599-4B61-A089-A90BAA2CC722 Q37335720-CE82FDA8-B1D9-465A-A5E9-7847B5DE1A0A Q37445943-8A81867F-E4A8-4A6A-95DD-29059276398F Q37499358-7867CF2C-FCF8-4F8C-8F10-72B21CAC4990 Q37688257-AD27E8F4-E445-456F-9003-856756EA2284 Q38077591-4CB083D8-2005-4E00-8782-BC635D11E6BE Q38122347-508AB335-4AD7-4211-9F0D-519893045BFC Q38140015-E10B4C90-D1FC-4165-AF0A-61F52C1796BF Q38223105-9EB194B0-4A44-440E-905F-C9A98FACEC17 Q38237895-3224078F-0797-4F59-8A0E-D2973F295769 Q38284455-5C5BCABB-85EB-4709-A7BF-255EFE4308B2 Q38284468-75CAB1DC-E692-4CF7-8268-7302005F016F Q38341595-1EF0728B-2F55-4C11-86CE-A136FA1216E3 Q38391049-DEC584CC-B13C-4C14-A7E0-C131879CF4CF Q38400673-9221BB29-6E85-4A83-A628-1C03FC220DA4 Q38605129-BC3F8AF9-B4D2-4461-B660-93219D2A0DAF Q38738090-8D3B5548-C383-4FBF-A1DA-7AB05A246F53 Q38784762-1CE67FC7-CFB0-418B-9876-53CC7DABB269 Q38797864-4EEA8ADD-0F21-45FB-BECB-61CEE4FA5D2E Q38858839-A8ACED43-3F7E-40BD-BE95-0A0132CD2A39

P2860

Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.

http://www.wikidata.org/entity/Q36364013

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Multicenter study of posaconaz ...... ctors affecting concentration.

@ast

Multicenter study of posaconaz ...... ctors affecting concentration.

@en

type

label

Multicenter study of posaconaz ...... ctors affecting concentration.

@ast

Multicenter study of posaconaz ...... ctors affecting concentration.

@en

prefLabel

Multicenter study of posaconaz ...... ctors affecting concentration.

@ast

Multicenter study of posaconaz ...... ctors affecting concentration.

@en

P1433

Q36364013-3ACDDE54-F891-4328-9740-959316ADD7F5

P1476

Q36364013-23D6F6EA-908B-410C-8CC7-DB877953B24E

P2093

Q36364013-2E2BF880-6AEE-4E6A-A729-292E36D85F80

Q36364013-B7336CFB-B21F-4260-B9FA-80BCA3A25832

Q36364013-C979F929-72D0-4DD7-ACBC-E13AF84C5E0E

Q36364013-DF37898E-23F4-46F6-A4AF-FC5B9EDA1538

P2860

Q36364013-06AC5179-3D55-4128-B0A2-6894B06BAE16

Q36364013-0B8BB6CD-9D89-49EB-AEEC-2575DD9BC474

Q36364013-179B159B-FE39-4DD6-A42D-23FFF3C203AD

Q36364013-1DE77C20-84A8-4485-8E4E-EF5C78A01A80

Q36364013-1E456C5B-F7EE-4BD4-BA5C-1460AEF2BC63

Q36364013-3CE2D9C0-B3F0-47EC-A5C3-1DA8209233D5

Q36364013-407EE50E-AB8D-4910-9D65-88617E747AD5

Q36364013-414E5E7D-E660-4928-926D-A062828ED366

Q36364013-4BD660EB-B177-4CE5-B200-7E5BFE66F7E9

Q36364013-591160DC-82F9-4793-B297-A299D21E0854

P304

Q36364013-8FFEA6A5-22D0-4328-A6D5-2BB2506DEC65

P31

Q36364013-8C915DBB-40B7-4AAE-8FE4-EA629B6939E8

P356

Q36364013-5C6B78C3-F49D-4DB7-8E93-2E574C6937BF

P407

Q36364013-2C2D2A40-D114-48FE-A107-6987068EBED1

P433

Q36364013-4BD034D7-9F20-48D2-AD19-D5773CA906F1

P478

Q36364013-9381581A-D578-4F3D-8591-27BEA206501D

P50

Q36364013-CF1E0F99-1083-4C01-9B27-BE11DC182DB9

Q36364013-DE78AE61-8AD8-4083-887E-A11985ED7E9B

P577

Q36364013-93C3D05F-943E-49B1-9C31-219AD0E966BD

P698

Q36364013-7F0180E1-0AFA-4065-B9CD-33CB7AAA90C8

P921

Q36364013-DA8780A6-AB03-4F6A-BB52-798235EC77C4

P932

Q36364013-9B47D4D9-872C-43F7-964B-59BD9D131944

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Multicenter study of posaconaz ...... actors affecting concentration

@en

P2093

John E Ray

http://www.w3.org/2001/XMLSchema#string

Kingsley Ng

http://www.w3.org/2001/XMLSchema#string

Michael J Dolton

http://www.w3.org/2001/XMLSchema#string

Sharon C-A Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method

Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.

Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy

Relevance of timing for determination of posaconazole plasma concentrations

Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.

Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs.

Combination therapy for mucormycosis: why, what, and how?

Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.

P304

5503-5510

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00802-12

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J. McLachlan

P577

2012-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22890761

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3486529

http://www.w3.org/2001/XMLSchema#string